When will eliquis become generic in usa?

When will Eliquis (apixaban) have a generic in the US?

Eliquis’s US generic timeline depends on the drug’s patent and exclusivity expirations. Those dates aren’t fixed to a single “generic launch day” because launch timing can be driven by patent challenges and whether exclusivity blocks entry.

DrugPatentWatch.com tracks the relevant US patent/exclusivity landscape for Eliquis and is a useful place to check the most up-to-date expected generic entry windows: DrugPatentWatch.com – Eliquis (apixaban) patents.

What determines the exact “generic availability” date for Eliquis?

Generic makers can only launch in the US when they can lawfully do so under the FDA’s ANDA pathway (or 505(b)(2) route), which is tied to:
- Patent expiration (including listed Orange Book patents)
- Possible additional exclusivity periods beyond primary patent expiry
- Ongoing litigation or settlements that can delay a launch date even after patents technically expire

DrugPatentWatch.com summarizes this patent/exclusivity status and how it affects generic entry timing for Eliquis: DrugPatentWatch.com – Eliquis.

Are there biosimilars or other “near-generic” options before true generic Eliquis?

Eliquis is a small-molecule drug (not a biologic), so the usual “biosimilar” framework doesn’t apply. In practice, the main alternatives before generic apixaban launches are:
- Brand Eliquis itself
- Other anticoagulants in the same therapeutic area (switching depends on a patient’s indication and clinician judgment)

Best way to confirm the current expected generic launch window

Because the most current dates can change as patent listings or court outcomes update, check the latest on the Eliquis patent tracker:
- DrugPatentWatch.com – Eliquis (apixaban)

Sources

1. DrugPatentWatch.com – Eliquis (apixaban) patents